Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia 3Carcinoma, Non-Small-Cell Lung 3Neoplasms by Histologic Type 2Myeloproliferative Disorders 2Leukemia, Myeloid 2Hematologic Diseases 2Bone Marrow Diseases 2Small Cell Lung Carcinoma 1Piebaldism 1Malignant Hepatobiliary Neoplasm 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Accelerated Phase 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Blast Crisis 1Adenocarcinoma of Lung 1

Interventions

Carboplatin 41Paclitaxel 32Radiotherapy 28Cisplatin 25Bevacizumab 24Erlotinib Hydrochloride 19Pemetrexed 18Docetaxel 16Gemcitabine 15Gefitinib 8Vinorelbine 7Taxes 7Cetuximab 7ceritinib 5Surgical Procedures, Operative 5Etoposide 5Amplified Fragment Length Polymorphism Analysis 5sargramostim 3pembrolizumab 3capmatinib 3Radiotherapy, Conformal 3Radiation 3Gene Expression Profiling 3Cyclophosphamide 32-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a 3trametinib 2pegfilgrastim 2osimertinib 2Topotecan 2Tirapazamine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Adenocarcinoma of Lung × ponatinib × Clear all
NCT01935336 2022-02-11

Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers

University of Colorado, Denver

Phase 2 Completed
171 enrolled 13 charts
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡